Roivant Sciences Ltd. Common Shares
ROIVRoivant Sciences Ltd. is a pharmaceutical company focused on the development and commercialization of innovative medicines. The company employs a platform approach to accelerate the development of drug candidates across various therapeutic areas by creating and advancing specialized subsidiary companies, known as "Vant" ventures. Roivant aims to bring new treatments to market efficiently and improve patient outcomes through its innovative business model.
Company News
The myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB...
The generalized myasthenia gravis (gMG) market is experiencing significant growth with 8 promising late-stage drug candidates in development. The gMG market across 7 major markets was valued at USD 5.9 billion in 2025 and is projected to grow at 9.1% CAGR through 2036. Key therapies in development include FcRn inhibitors, complement inhibitors, B...
Priovant Therapeutics announced enrollment of the first subjects in a Phase 2b/3 clinical trial of brepocitinib for lichen planopilaris (LPP), marking the fourth indication in the drug's late-stage development program. The company expects a potential FDA approval for brepocitinib in dermatomyositis in Q3 2026, with additional Phase 3 data expecte...
Priovant Therapeutics announced that its Phase 3 VALOR trial of brepocitinib 30 mg met its primary endpoint for treating dermatomyositis, showing superior efficacy to placebo across multiple measures including muscle strength, skin disease, and corticosteroid reduction. The FDA has granted Priority Review with a PDUFA target action date in Q3 202...
Moderna settled a long-running legal dispute over COVID-19 vaccine technology, paying $2.25 billion to Roivant Sciences' Genevant unit and Arbutus Biopharma—less than the $3 billion expected. While Moderna stock surged 15.99% on the news, analysts suggest it now trades 22% above fair value after a 108% six-month rally. The article identifies 9 ...
